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Sickle cell disease (SCD) was the first well-documented molecular 
disease[1] and is the most prevalent monogenic disease in the world. 
SCD is an accepted worldwide health problem that is comparable 
to other major global diseases such as diabetes, hypertension and 
communicable diseases.[2] Sub-Saharan Africa (SSA) has the highest 
burden of SCD disease, with in excess of 300 000 new affected births 
annually, accounting for 80% of all annual affected child births 
globally.[3] In spite of the high burden of disease in SSA, SCD is often 
associated with limited to poor medical resources, infrastructure 
and quality of care, so estimates of neonatal and childhood mortality 
remain high, with up to 90% of affected children dying by 5 years 
of age.[4] SCD is caused by the polymerisation and precipitation of 
the β-globin chains (HbS) during deoxygenation and dehydration 
of erythrocytes.[5] The altered structure of erythrocytes (normal 
biconcave shape to a crescent shape) is the basis of the vascular 
pathology of the disease, which includes abnormality of platelet and 
leucocyte adhesion and hypercoagulation leading to microvascular 
occlusion, haemolysis, hypoxia, failed nitric oxide production and 
multiorgan damage. [5] The hallmark phenotypes of the disease 
include vaso-occlusive crises, stroke and acute chest syndrome. [5-7] 
The phenotype of SCD is influenced by both environmental 
and genetic factors. Variants at three principal loci, BCL11A, 
HBS1L-MYB intergenic polymorphism and the β-globin haplotype, 
have been shown to account for 10 - 20% of the variance of 
fetal haemoglobin (HbF) levels and to be associated with the 
amelioration of SCD symptoms. [8-10] Other variants in the BCL11A 
erythroid-specific enhancer (rs1427407 and rs7606173) have been 
shown to account for 8% and 6.2% of HbF variance, respectively, 
among SCD patient cohorts in the USA,[11,12] Tanzania[13] and 
Cameroon.[14] The co-inheritance of α-thalassaemia has also been 
associated with improved clinical manifestations of SCD.[15-18] 
Although the multiple independent origins of the HbS mutation 
have been questioned recently,[19] the SCD mutation is classically 
associated with five region-defined β-globin gene haplotypes, 
Benin, Bantu or Central African (CAR), Cameroon, Senegal and 
Indian-Arab,[20-23] four of which are from Africa and associated with 
malaria incidence.[24]
Because of the low incidence of malaria, the incidence of SCD in 
South Africa (SA) is equally extremely low; the HbS allele can be 
found in some indigenous SA ethnic groups (Venda and Shangaan) 
at an approximated frequency of 0.2%.[25-26] However, this is changing 
with the socioeconomically motivated influx of immigrants from 
other African countries, especially those within the equatorial 
malaria-endemic belt, resulting in a 300 - 400% increase in new cases 
of SCD over the past 10 years at Red Cross War Memorial Children’s 
Hospital (RCWMCH) in Cape Town, SA.[27] The existence of similar 
trends in adult SCD patient services has not been investigated. 
Following our previous report at RCWMCH, we report in the present 
study the trend of new cases of adolescent and adult SCD over the 
past 20 years, having studied the clinical, haematological and genetic 
profiles of a cohort of 34 adolescent and adult SCD patients at the 
Haematology Unit at Groote Schuur Hospital (GSH), Cape Town.
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Background. An exponential increase in the number of sickle cell disease (SCD) patients in paediatric services in Cape Town, South Africa, 
has been reported. The trend in adult/adolescent services has not been investigated.
Objectives. To evaluate epidemiological trends of SCD and the profile of patients affected by SCD attending the Haematology Clinic at 
Groote Schuur Hospital (GSH), Cape Town.
Methods. (i) A retrospective review of the number of SCD patients over the past 20 years; (ii) a cross-sectional analysis of clinical and 
haematological characteristics of SCD patients; and (iii) molecular analysis of the haemoglobin S mutation, the haplotype in the β-globin-
like genes cluster, the 3.7 kb α-thalassaemia gene deletion and 19 selected single-nucleotide polymorphisms (SNPs) associated with fetal 
haemoglobin (HbF) levels.
Results. From 1995 to 2016, 81 adolescent/adult patients with SCD were registered, mostly originating from other African countries (n=61, 
75.3%). There was an increase of over 200% in new cases (n=47) during the last quarter of the two decades investigated. Data from 34 of 58 
regular attendees (58.6%) were analysed. The mean age of the patients was 26.1 years (standard deviation (SD) 9.8), and 70.6% were male. 
With the exception of four patients with sickle/β-thalassaemia, all the patients had SCD (haemoglobin SS). The co-inheritance of a single 
3.7 kb α-globin deletion was found in 42.3% of cases (n=11). The Bantu haplotype was the most observed (65.4% of chromosomes). Most 
HbF-promoting SNPs were not associated with variable levels of haematological indices.
Conclusions. There is an increasing burden of adult SCD patients at GSH. National health and academic institutions need to adapt policies 
and healthcare professional training accordingly.
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The study was performed in accordance with the Declaration of 
Helsinki and with the approval of the Faculty of Health Sciences 
Human Research Ethics Committee, University of Cape Town 
(HREC ref. no. 132/2010). Informed and written consent was 
obtained from adult participants (≥18 years), and for one patient 
aged 15 years informed consent was obtained from the guardian with 
assent from the participant.
Patients
The Haematology Clinic runs weekly every Wednesday. Most 
patients are seen at least once a month, and clinically stable patients 
every 3 months, with the exception of crisis-related hospitalisation. 
A retrospective review of the number of SCD patients attending the 
clinic over the past 20 years and a cross-sectional analysis of patients 
who regularly attend the clinic were performed. Clinical events and 
haematological indices were retrospectively collected from hospital 
records. The haematological measures were those reported at the first 
visit to the hospital.
Molecular methods
DNA extraction
DNA was isolated from the peripheral blood using the AllPrep 
DNA/RNA/miRNA universal kit (Qiagen, USA) according to the 
manufacturer’s instructions.
Genotyping
HbS mutation and β-globin haplotypes
Polymerase chain reaction (PCR) and DdeI restriction analysis 
were used to confirm the presence of the HbS mutation using 
100  ng DNA. [28] Published primers and methods[29] genotyping five 
restriction fragment length polymorphic regions in the β-globin gene 
cluster were used to analyse XmnI (5ʹGγ), HindIII (Gγ), HindIII 
(Aγ), HincII (3˙ʹΨβ) and HinfI (5ʹβ) to determine the β-globin 
haplotype background.[19]
Single-nucleotide polymorphisms (SNPs)
Using a reported method,[9] SNaPshot genotyping, capillary electro-
phoresis and direct cycle sequencing were used to assay five selected 
HbF-associated variants: rs8176703, rs372091, rs2334880, rs1427407 
and rs7606173. In addition, 18 other variants were analysed using the 
iPLEX Gold Sequenom Mass Genotyping Array (Inqaba Biotec, SA): 
X12_123681790, X16_391593, rs10468869, rs10756993, rs113267280, 
rs11754265, rs141494605, rs148706947, rs183437571, rs192197462, 
rs570013781, rs59329875, rs62573842, rs6466533, rs6590706, 
rs67104793, rs7163278 and rs76901220.
Statistical analysis
Descriptive statistics were obtained for all quantitative data using 
SPSS version 21.0 (IBM, USA). A χ2 test with one degree of freedom 
was used to perform the Hardy-Weinberg Equilibrium (HWE) test 
on the SNP genotypes with all variants in HWE (p>0.05).
Results
Patients’ origin and trends
A total of 128 patients’ files from 1995 to March 2016 were reviewed. 
Among them, 47 patients were diagnosed with some form of α- or 
β-thalassaemia (Fig. 1). Of the remaining 81 patients affected by 
SCD, 61 (75.3%) were from other SSA countries. Over the last quarter 
(2011 - 2016) of the past two decades, there was an approximately 
200% increase in new cases of SCD registered at the GSH Haema-
tology Clinic (n=47) (Fig. 2). Fig. 3 shows the number of patients 
seen at GSH (A) and countries of origin (B), with 16.4% (n=21) SA 
patients, most of whom are of mixed/Indian ancestry (n=15), and 
21.9% (n=28) from the Democratic Republic of Congo (DRC).
Of the 58 patients who regularly attend the Haematology Clinic, 
34 (58.6%) consented to inclusion in the study (Fig. 1). Over 75% 
of the patients at GSH were referrals from RCWMCH, with others 
coming from neighbouring secondary-level hospitals in Cape Town 
and a minority of internal referrals of relatives of attending patients.
Clinical and haematological profile
The mean age was 26.1 years (standard deviation (SD) 9.8, range  15 - 
51), and 70.6% were male. The rate of co-inheritance of a single 
3.7 kb α-globin gene deletion was 42.3% (n=11).
Table 1 summarises the haematological and clinical events recorded 
for all patients. Information obtained from the anamnesis indicated 
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Fig. 2. Incidence trend of SCD at GSH over 20 years.
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age at diagnosis 6.8 years (SD 7.1), range 1 - 
39), as a result of the presentation of the 
initial clinical manifestations of SCD, mainly 
pain episodes.
Clinical management
With regard to treatment, 33.3% (n=10) of 
the patients in the cohort had received at 
least one blood transfusion. About 16.7% 
(n=5) of the patients had been enrolled in a 
hypertransfusion programme, ranging from 
a fortnightly to monthly transfusion regimen, 
to manage complications such as stroke, 
chronic pain crises and non-healing chronic 
leg ulcers. The frequency of transfusions 
is largely dependent on symptom severity 
and availability of blood units from the 
Western Cape Blood Transfusion Service, 
Cape Town, SA.
Of the patient cohort, 86.6% (n=26) were 
at maximum tolerated dose of hydroxyurea 
(HU) with dosages ranging between 500 
and 1 000 mg/d. From our patient survey, 
30 - 50% of the participants were fully 
compliant with HU treatment, 20 - 30% 
reported partial compliance (tending to 
forget to take the treatment two to three 
times a week), and some patients refused 
treatment. Reasons for refusal included 
potential cancer development in the future, 
family planning, particularly for men 
afraid of treatment-related infertility, and 
self-perceived improvement of symptoms 
without the treatment.
Genetic characteristics
Sickle cell genotypes: β-globin haplotypes 
and co-inheritance of α-thalassaemia
The description of the HbS allele fre-
quency, β-globin haplotype background 
and α-globin gene deletion for the patients 
is given in Table 1. Genotyping for 
the HbS mutation revealed that 85.2% 
(n=23) of the patients were homozygous 
for the mutation (haemoglobin SS), with 
the rest being heterozygous (haemoglobin 
AS)  with a possibility of β0-thalassaemia 
(HbS/β0) (n=4), all of whom were South 
African with mixed and Indian ancestry. 
Fig. 4 shows the distribution of the SCD 
β-globin gene haplotypes: the Bantu and 
Atypical haplotypes accounted for 65.4% 
and 26.9%, respectively, whereas the Sene-
gal and Benin haplotypes accounted for 
3.8% each, with no observation of the 
Cameroon and Indian-Arab haplotypes. In 
combination, the Bantu/Bantu haplotype 
represented 50.0% of the patients (Table 1). 
The heterozygous 3.7 kb α-globin gene 
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Fig. 3. Numbers and percentages of patients by nationality (A) and the distribution of countries of birth 
for patients at GSH (B).
Table 1. Description of haematological indices, clinical events and globin genes  
of the study cohort
Variables % or mean (SD) Value range n
Gender
Female 29.4 - 10
Male 70.6 - 24
Age (years) 26.1 (9.8) 15 - 51 34
Haematological indices
Haemoglobin (g/dL) 9.1 (1.8) 5.6 - 14.0 27
MCV (fL) 91.5 (31.9) 53.6 - 146.4 27
WBCs (× 109/L) 8.1 (3.0) 3.0 - 13.6 27
Platelets (× 109/L) 334 (166.5) 133 - 737 27
Neutrophils (× 109/L) 4.6. (1.5) 2.0 - 10.3 27
Clinical events
Age at diagnosis (years) 6.8 (7.1) 1 - 39 30
Vaso-occlusive crisis (number/year) 1.5 (1.2) 0 - 5 30
Stroke 13.3 - 4/30
Leg ulcers 16.7 - 5/30
Hospitalisations (number/year) 2.1 (1.4) 0 - 5 30
Treatment
Blood transfusions 33.3 - 10/30
HU (mg/d) 544.1 (144) 500 - 1 000 30
β-globin genotype
HbSS 85.2 - 23/27
HbAS 14.8 - 4/27
β-globin haplotype
Bantu/Bantu 50.0 - 13/26
Bantu/Senegal 7.7 - 2/26
Bantu/Benin 7.7 - 2/26
Bantu/Atypical 15.4 - 4/26
Atypical 19.2 - 5/26
α-globin gene deletion
αα/αα 57.7 - 15/26
αα/α3.7 42.3 - 11/26
MCV = mean corpuscular volume; WBCs = white blood cells; HbSS = haemoglobin SS; HbAS = haemoglobin AS.
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Frequency of genetic variants 
associated with HbF levels
Table 2 shows the observed alleles and 
minor allele frequency (MAF) of genetic 
variants previously associated with HbF, 
some recently in a Sardinian population. [30] 
All variants were in HWE (p>0.05) with 
the exception of four loci (X12_123681790, 
rs141494605, rs183437571 and rs192197462) 
that presented monomorphic alleles in all 
patients. Tests of association between the 
variants and all haematological indices inclu-
ding Hb levels were conducted; how ever, 
no significant associations were observed 
except for rs6466533 and the SCD haplotype 
combinations. The CC genotype (rs6466533) 
was associated with higher platelet counts 
than the heterozygous TC genotype (p<0.05). 
Similarly, the Bantu/Bantu haplotype com-
bination was associated with higher platelet 
counts than the Atypical/Atypical genotype 
(p<0.05). Table 3 shows the MAF of the 
above variants in African populations: 
Esan (Nigeria), Luhya (Kenya), Mandinka 
(Gambia) and Mende (Sierra Leone); Ameri-
can (including African-American), European 
and both East and South Asian populations.
Discussion
To the best of our knowledge, this is the 
first study describing the clinical and genetic 
backgrounds of SCD patients at GSH and 
reporting on adult patients with SCD in SA. 
The results of this study indicate a similar 
trend of a rapid increase in the number of 
cases of SCD that was previously reported at 
RCWMCH in Cape Town.[27] This was also 
the result of migration from SSA countries 
where SCD is most prevalent. Related to 
this was a specific administrative difficulty 
in taking care of some patients who lack 
the up-to-date and correct paperwork for 
immigrants and asylum seekers. This was 
an indirect indication that most patients 
arrived as adults in SA, contrary to the 
observation in the second part of the last 
decade at RCWMCH, where most patients 
were SA born. It is therefore expected that 
the adult SCD population at GSH will 
continue to grow from the compounded 
effects of future referrals from neighbouring 
paediatric hospitals and the arrival of new 
adult patients from migrant populations, as 
migration, particularly into SSA, continues 
to be the reality for many people seeking 
political asylum, economic opportunities 
and better healthcare. Concomitant with this 
migration, the improved clinical management 
and healthcare of paediatric SCD patients 
is expected to increase the pool of adult 
patients living with SCD. This will increase 
the number of patients who will survive well 
beyond reproductive age, which is likely to 
increase the frequency of the HbS allele in the 
population.
Newborn screening and comprehensive 
clini cal care programmes, which are also 
possible in SA, have reduced SCD-rela ted 
premature childhood deaths by 70% in high-
income nations such as the USA,[31,32] and 
most patients can survive into adulthood. [33] 
A similar increasing trend of SCD in countries 
previously not affec ted by the disease 
has been observed in Ireland,[34] Italy,[35] 
Germany,[36] England[37] and France.[38] 
There fore, the evidence that the SCD burden 
is comparable to that of communicable 
diseases and other major global diseases 
such as hypertension and diabetes[2] will have 










Fig. 4. Distribution of SCD haplotypes by number and percentage of chromosomes.
Table 2. Genetic variants previously associated with HbF
SNP Chromosome loci Alleles MAF n
rs8176703 136135863* G/A 0.130 27
rs372091 11:5496926 G/A 0.148 27
rs2334880 16:71619734 C/T 0.400 25
rs1427407 2:60490908 C/A 0.204 27
rs7606173 2:60498316 C/G 0.426 27
X12_123681790 X12_123681790 A† - 31
X16_391593 X16_391593 T/C 0.015 33
rs10468869 18:51795403 A/G 0.400 30
rs10756993 9:18839726 C/A 0.016 31
rs113267280 6:41952511 T/G 0.016 31
rs11754265 6:135356216 C/G 0.172 29
rs141494605 16:216593 T† - 27
rs148706947 16:342218 C/T 0.047 32
rs183437571 19:13121899 C† - 30
rs192197462 14:57116065 A† - 30
rs570013781 16:149539 G/A 0.016 31
rs59329875 20:44547672 C/T 0.296 27
rs62573842 9:32264314 A/G 0.250 30
rs6466533 7:79163576 T/C 0.283 30
rs6590706 11:133465011 A/G 0.217 30
rs67104793 3:142444839 A/DEL.A 0.190 29
rs7163278 15:93345162 T/C 0.121 29
rs76901220 ss131769967* G/A 0.016 31
*No chromosome location provided in dbSNP, reference ID provided.
†Monomorphic.
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in patients between 2001 and 2005 
could also be asso ciated with the 
ending of a civil war, a transitional 
government and political instability 
in DRC, the effects of which had 
spread into neighbouring states. The 
more recent increase (2011 - 2016) 
is more likely to be due to economic 
and health-motivated migration. The 
increase of SCD in both paediatric 
and adult settings will impose a new 
burden on the healthcare system in 
SA concomitant with a new need 
for training at all levels of medical 
education, as well as the need for 
policies from health authorities for 
the prevention, management and 
care of haemoglobinopathies.
The number of annual vaso-
occlusive crises was similar to that 
reported in Cameroon, as was the 
mean number of vaso-occlusive 
crises per year.[9] Major challenges 
faced by healthcare professionals at 
GSH were patient compliance with 
HU treatment, compliance with 
supportive medication such as folic 
acid and patient clinic attendance. 
There were several barriers to HU 
treatment, including the financial 
implications of taking time off work 
to attend the clinic and receive it 
(maximum one month’s supply), and 
misconceptions about the treatment 
and its possible carcinogenic effects, 
as well as potential impotence in male 
patients.[39] Most patients who fail to 
comply with clinic appointments do 
so simply because they feel better 
and therefore see no need to go to 
the hospital.
The novel aspect of this article 
is the report on the genetic back-
ground of four key modifiers of HbF: 
variants at the BCL11A erythroid-
specific enhancer, β-globin haplo-
types, α-thala ssaemia 3.7 kb gene 
dele tion and several other known 
HbF-promoting polymorphisms. It 
is imperative to gain a better under-
standing of genetic variants affecting 
the predisposition to specific com-
plications such as stroke and acute 
chest syndrome, and polymorphisms 
affecting susceptibility to pain, as well 
as the pharmacogenomics of com-
monly prescribed treatments such as 
HU, malaria prophylaxis and pain 
medication. The dominance of the 
Bantu haplotype in this cohort is in 
accordance with the Congolese origin 
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haplotype is most prevalent below the equatorial malaria belt across 
southern African countries.[19] Most variants were not associated with 
haematological indices except the CC genotype at rs6466533 and 
Bantu/Bantu haplotype combination with platelet counts, probably 
because of the modest sample size. The differences in MAF of the 
recently identified HbF-promoting loci in a Sardinian population[30] 
among African populations from the Human 1000 Genome Project 
(1000G) (Table 3) emphasises the necessity of large-scale genomic 
analyses on various populations across the continent, as there are vast 
variations between any two African populations.
It should be made clear that the intention of this article is not to 
stigmatise SCD nor immigrant patients, but to inform and prepare 
medical care providers and healthcare officials of the increasing 
need for management of haemoglobinopathies in SA. This trend 
is not restricted to SA, with countries such as Italy[40] the Republic 
of Ireland,[34] England[41] and Germany[36] affected by the reality 
of population movement and new burden of disease, developing 
neonatal screening programmes and establishing SCD centres in 
response to similar increases in SCD prevalence.
Study limitations
The final sample size of patients included in the present study was 
limited because of poor patient compliance with clinic attendance, self-
transfers to other hospitals and the shortened period of recruitment. 
The sample size did not allow for robust statistical analyses to reveal 
potent markers of specific phenotypes or clinical measures. HbF 
levels were measured for a handful of patients performed using 
high performance liquid chromatography before initiation of HU 
treatment. This haematological measure would have been ideal to 
check for association with genetic variants as baseline HbF.
Conclusions
Over the past 10 years, the number of adult patients living with 
SCD has increased considerably, imposing the creation of a weekly 
outpatient service at GSH. The genetic profile is similar to that of 
many other SCD patients from the other SSA countries from where 
most patients originate. The trend has a number of implications, 
particularly for medical education at academic and training 
institutions, policy action on prevention and care at the National 
Department of Health, and research in haemoglobinopathies in SA.
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